MCID: PRT096
MIFTS: 53

Peritoneal Mesothelioma

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Peritoneal Mesothelioma

MalaCards integrated aliases for Peritoneal Mesothelioma:

Name: Peritoneal Mesothelioma 12 15 73
Malignant Mesothelioma of Peritoneum 12 73
Advanced Malignant Mesothelioma of Peritoneum 12
Advanced Malignant Peritoneal Mesothelioma 12
Advanced Peritoneal Malignant Mesothelioma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1788
ICD10 33 C45.1
NCIt 50 C8704 C9350

Summaries for Peritoneal Mesothelioma

Disease Ontology : 12 A peritoneum cancer that develops from cells of the mesothelium and is located in the peritoneum.

MalaCards based summary : Peritoneal Mesothelioma, also known as malignant mesothelioma of peritoneum, is related to malignant peritoneal mesothelioma and adenocarcinoma, and has symptoms including abdominal pain An important gene associated with Peritoneal Mesothelioma is BAP1 (BRCA1 Associated Protein 1), and among its related pathways/superpathways are Pathways in cancer and Glioblastoma Multiforme. The drugs Doxorubicin and Doxil have been mentioned in the context of this disorder. Affiliated tissues include ovary, colon and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Peritoneal mesothelioma is the name given to the cancer that attacks the lining of the abdomen. This... more...

Related Diseases for Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 malignant peritoneal mesothelioma 33.7 CDKN2A EGFR MUC1 NF2
2 adenocarcinoma 30.4 CDKN2A EGFR MUC1
3 mucinous adenocarcinoma 29.9 CDKN2A EGFR MUC1
4 renal cell carcinoma, nonpapillary 29.8 EGFR MUC1 WT1
5 malignant peripheral nerve sheath tumor 29.6 CDKN2A EGFR MUC1 NF2
6 benign multicystic peritoneal mesothelioma 12.7
7 benign peritoneal mesothelioma 12.4
8 peritoneal cystic mesothelioma 11.7
9 benign mesothelioma 10.5
10 lymphohistiocytoid mesothelioma 10.2 CDKN2A THBD
11 anaplastic oligodendroglioma 10.2 CDKN2A EGFR
12 hepatoid adenocarcinoma 10.2 EGFR MUC1
13 bile duct adenoma 10.2 CDKN2A MUC1
14 cholangiolocellular carcinoma 10.2 CDKN2A MUC1
15 pleomorphic liposarcoma 10.2 CDKN2A MUC1
16 inguinal hernia 10.2
17 ischemic fasciitis 10.2 CDKN2A MUC1
18 mucinous bronchioloalveolar adenocarcinoma 10.2 CDKN2A MUC1
19 well-differentiated liposarcoma 10.2 CDKN2A MUC1
20 transitional meningioma 10.2 MUC1 NF2
21 fibrous meningioma 10.2 MUC1 NF2
22 basaloid squamous cell carcinoma 10.2 CDKN2A EGFR
23 plasmablastic lymphoma 10.2 CDKN2A MUC1
24 cervical adenosquamous carcinoma 10.2 CDKN2A EGFR
25 pericardial mesothelioma 10.2 MUC1 THBD
26 optic nerve sheath meningioma 10.2 CDKN2A NF2
27 chordoid glioma 10.2 MUC1 NF2
28 oncocytic breast carcinoma 10.2 EGFR ESR1
29 meningeal melanocytoma 10.2 CDKN2A MUC1
30 cornea cancer 10.2 CDKN2A NF2
31 biliary tract neoplasm 10.2 CDKN2A MUC1
32 vulva cancer 10.1 CDKN2A EGFR
33 rhabdoid meningioma 10.1 BAP1 NF2
34 anaplastic ependymoma 10.1 MUC1 NF2
35 atypical neurofibroma 10.1 CDKN2A NF2
36 apocrine adenocarcinoma 10.1 ESR1 MUC1
37 laryngeal disease 10.1 CDKN2A EGFR
38 bartholin's gland benign neoplasm 10.1 CDKN2A ESR1
39 oropharynx cancer 10.1 CDKN2A EGFR
40 inflammatory breast carcinoma 10.1 EGFR ESR1
41 syringoma 10.1 ESR1 MUC1
42 endometrial squamous cell carcinoma 10.1 CDKN2A ESR1
43 pseudomyxoma peritonei 10.1
44 peritonitis 10.1
45 intestinal obstruction 10.1
46 gelatinous ascites 10.1
47 adenoid basal cell carcinoma 10.1 CDKN2A ESR1
48 spindle cell sarcoma 10.1 MUC1 NF2
49 malignant epithelial mesothelioma 10.1 THBD WT1
50 endocervical carcinoma 10.1 CDKN2A ESR1

Graphical network of the top 20 diseases related to Peritoneal Mesothelioma:



Diseases related to Peritoneal Mesothelioma

Symptoms & Phenotypes for Peritoneal Mesothelioma

UMLS symptoms related to Peritoneal Mesothelioma:


abdominal pain

GenomeRNAi Phenotypes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.83 EGFR
2 Decreased viability GR00221-A-1 9.83 CDKN2A EGFR ESR1 LATS2
3 Decreased viability GR00221-A-2 9.83 ESR1 LATS2
4 Decreased viability GR00221-A-3 9.83 CDKN2A
5 Decreased viability GR00221-A-4 9.83 CDKN2A EGFR ESR1 LATS2
6 Decreased viability GR00402-S-2 9.83 CDKN2A EGFR ESR1 LATS2

MGI Mouse Phenotypes related to Peritoneal Mesothelioma:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.19 BAP1 BIRC3 CDKN2A EGFR ESR1 LATS2
2 cellular MP:0005384 10.18 BAP1 BIRC3 CDKN2A EGFR ESR1 LATS2
3 embryo MP:0005380 10.16 BAP1 CDKN2A EGFR ESR1 LATS2 NF2
4 homeostasis/metabolism MP:0005376 10.16 BAP1 BIRC3 CDKN2A EGFR ESR1 LATS2
5 growth/size/body region MP:0005378 10.14 BAP1 CDKN2A EGFR ESR1 LATS2 NF2
6 immune system MP:0005387 10.1 BAP1 BIRC3 CDKN2A EGFR ESR1 NF2
7 endocrine/exocrine gland MP:0005379 10.09 BAP1 CDKN2A EGFR ESR1 LATS2 NF2
8 mortality/aging MP:0010768 10.09 BAP1 BIRC3 CDKN2A EGFR ESR1 LATS2
9 hematopoietic system MP:0005397 10.07 BAP1 BIRC3 CDKN2A EGFR ESR1 THBD
10 liver/biliary system MP:0005370 10 CDKN2A EGFR ESR1 LATS2 NF2 THBD
11 digestive/alimentary MP:0005381 9.97 BAP1 CDKN2A EGFR ESR1 THBD
12 integument MP:0010771 9.95 BAP1 CDKN2A EGFR ESR1 NF2 THBD
13 muscle MP:0005369 9.95 BAP1 BIRC3 CDKN2A EGFR ESR1 LATS2
14 neoplasm MP:0002006 9.85 BAP1 CDKN2A EGFR ESR1 NF2 WT1
15 no phenotypic analysis MP:0003012 9.8 BAP1 CDKN2A EGFR ESR1 LATS2 WT1
16 normal MP:0002873 9.73 BIRC3 EGFR ESR1 LATS2 THBD WT1
17 renal/urinary system MP:0005367 9.55 EGFR ESR1 NF2 THBD WT1
18 reproductive system MP:0005389 9.5 BAP1 CDKN2A EGFR ESR1 NF2 THBD
19 respiratory system MP:0005388 9.17 BAP1 CDKN2A EGFR ESR1 NF2 THBD

Drugs & Therapeutics for Peritoneal Mesothelioma

Drugs for Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Doxil Approved June 1999 Phase 3,Phase 2 31703
3 Ranpirnase Investigational Phase 3 196488-72-9
4 Antibiotics, Antitubercular Phase 3,Phase 2
5 Anti-Bacterial Agents Phase 3,Phase 2
6 Topoisomerase Inhibitors Phase 3,Phase 2
7
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
8
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
9
Gemcitabine Approved Phase 2 95058-81-4 60750
10
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
11
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
12
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 6055-19-2, 50-18-0 2907
13
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 439693 40926
14
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
15
leucovorin Approved Phase 2,Phase 1 58-05-9 6006 143
16
Fluorouracil Approved Phase 2 51-21-8 3385
17
Promethazine Approved, Investigational Phase 2 60-87-7 4927
18
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
19
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
20
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
21
Pancrelipase Approved, Investigational Phase 2 53608-75-6
22
Ranitidine Approved Phase 2 66357-35-5, 66357-59-3 3001055
23
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
24
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
25
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
26
Bevacizumab Approved, Investigational Phase 2 216974-75-3
27
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
28
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
30
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
31
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
32 Antiviral Agents Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 2
34 Immunologic Factors Phase 2,Phase 1
35 Immunosuppressive Agents Phase 2,Phase 1
36 Anti-Infective Agents Phase 2,Phase 1
37 Antimetabolites Phase 2
38 Antibodies, Monoclonal Phase 2,Phase 1
39 Immunoglobulins Phase 2,Phase 1
40 Antibodies Phase 2,Phase 1
41 Interferon-gamma Phase 2
42 Alkylating Agents Phase 2,Phase 1
43 Mitomycins Phase 2
44 interferons Phase 2,Phase 1
45 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
46 Antineoplastic Agents, Alkylating Phase 1, Phase 2
47 Antirheumatic Agents Phase 1, Phase 2,Phase 2
48 Immunotoxins Phase 1, Phase 2,Phase 2
49
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
50 Protein Kinase Inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
3 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
4 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
5 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
6 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Unknown status NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
7 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed NCT01592383 Phase 2 erlotinib hydrochloride
8 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
9 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Completed NCT01160458 Phase 2 IMC-A12
10 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
11 Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma Recruiting NCT03644550 Phase 2 LMB-100
12 Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Recruiting NCT02588781 Phase 2 Pemetrexed
13 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
14 Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
15 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma Active, not recruiting NCT01843374 Phase 2 Tremelimumab;Placebo
16 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Active, not recruiting NCT02151448 Phase 1, Phase 2 Celecoxib;Interferon Alfa-2b
17 Pembrolizumab in Treating Patients With Malignant Mesothelioma Active, not recruiting NCT02399371 Phase 2
18 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2 Mitomycin C
19 Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma Completed NCT02141347 Phase 1 Tremelimumab;MEDI4736
20 Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Completed NCT00402766 Phase 1 Cisplatin;Imatinib Mesylate;Pemetrexed;Dexamethasone
21 Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma Recruiting NCT03608618 Phase 1
22 Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Active, not recruiting NCT02029690 Phase 1 ADI-PEG 20
23 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Active, not recruiting NCT02798536 Phase 1 LMB-100;nab-paclitaxel
24 Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Active, not recruiting NCT01439152 Phase 1 BAY94-9343;BAY94-9343 (Expansion);BAY94-9343 (1.8 mg/kg);BAY94-9343 (2.2 mg/kg)
25 CAR T Cells in Mesothelin Expressing Cancers Active, not recruiting NCT03054298 Phase 1
26 Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies Not yet recruiting NCT03546426 Phase 1 Pembrolizumab;Interleukin-2
27 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma Suspended NCT03436732 Phase 1 LMB-100;SEL-110
28 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
29 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
30 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy Recruiting NCT01416714
31 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
32 An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Recruiting NCT02754115
33 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
34 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169

Search NIH Clinical Center for Peritoneal Mesothelioma

Genetic Tests for Peritoneal Mesothelioma

Anatomical Context for Peritoneal Mesothelioma

MalaCards organs/tissues related to Peritoneal Mesothelioma:

41
Ovary, Colon, Lung, Lymph Node, Pancreas, Bone, Prostate

The Foundational Model of Anatomy Ontology organs/tissues related to Peritoneal Mesothelioma:

19
The Peritoneum

Publications for Peritoneal Mesothelioma

Articles related to Peritoneal Mesothelioma:

(show top 50) (show all 646)
# Title Authors Year
1
Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. ( 29503128 )
2018
2
Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. ( 29797583 )
2018
3
Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. ( 29431036 )
2018
4
Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases. ( 29048219 )
2018
5
Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival. ( 29721724 )
2018
6
Benign multicystic peritoneal mesothelioma treated with laparoendoscopic single site surgery: a case report and review of the literature. ( 29372166 )
2018
7
The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking. ( 29651664 )
2018
8
Malignant peritoneal mesothelioma in a woman with bilateral ovarian serous borderline tumour: Potential interactions between the two diseases. ( 29915796 )
2018
9
Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. ( 29260418 )
2018
10
Malignant Peritoneal Mesothelioma in the setting of a Ventriculo-Peritoneal Shunt: A novel clinical presentation. ( 29899672 )
2018
11
Malignant peritoneal mesothelioma in patients with endometriosis. ( 29794065 )
2018
12
Malignant Peritoneal Mesothelioma Presenting as Mucinous Ascites. ( 29577057 )
2018
13
Analysis of prognostic factors of patients with malignant peritoneal mesothelioma. ( 29506546 )
2018
14
Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma. ( 29423664 )
2018
15
Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study. ( 29978366 )
2018
16
Prognostic Significance of Blood, Serum, and Ascites Parameters in Patients with Malignant Peritoneal Mesothelioma or Peritoneal Carcinomatosis. ( 29643915 )
2018
17
Benign Multicystic Peritoneal Mesothelioma in a Male Patient with Previous Wilms' Tumor: A Case Report and Review of the Literature. ( 30155337 )
2018
18
An unusual cause of acute surgical abdomen: benign multicystic peritoneal mesothelioma associated with adenomatous tumor. ( 30534842 )
2018
19
Tumor Symbiosis: Gastrointestinal Stromal Tumor as a Host for Primary Peritoneal Mesothelioma. ( 30132292 )
2018
20
IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma. ( 30031101 )
2018
21
First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications. ( 30111295 )
2018
22
Malignant Peritoneal Mesothelioma in an Infant With Familial ATM Mutations. ( 30124550 )
2018
23
Malignant Peritoneal Mesothelioma: A Rare Cause of Ascites. ( 30349836 )
2018
24
Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. ( 30386115 )
2018
25
ASO Author Reflections: Management of Malignant Peritoneal Mesothelioma. ( 30421065 )
2018
26
Malignant peritoneal mesothelioma: a review. ( 30450291 )
2018
27
Update on the management of malignant peritoneal mesothelioma. ( 30450299 )
2018
28
Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types. ( 30510965 )
2018
29
Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members. ( 30001711 )
2018
30
Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia. ( 30143249 )
2018
31
ASO Author Reflections: Long-Term Survival Is Feasible After Complete CRS/HIPEC for Biphasic Peritoneal Mesothelioma. ( 30421064 )
2018
32
Malignant pleural and peritoneal mesothelioma: clinical update 2018. ( 30450287 )
2018
33
Well differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry. ( 30473172 )
2018
34
Malignant peritoneal mesothelioma: a review. ( 28706904 )
2017
35
Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. ( 29184697 )
2017
36
Remote Recurrence of Benign Multicystic Peritoneal Mesothelioma. ( 28733062 )
2017
37
Reproducibility for histologic parameters in peritoneal mesothelioma. ( 28712777 )
2017
38
Malignant peritoneal mesothelioma - a rare cause of laparotomy. ( 28702106 )
2017
39
A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. ( 29019584 )
2017
40
Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation. ( 28469343 )
2017
41
Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. ( 28100259 )
2017
42
A case of malignant peritoneal mesothelioma suggesting the utility of combining double-contrast radiography and endoscopy with computed tomography for diagnosis. ( 28646342 )
2017
43
Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array. ( 28829357 )
2017
44
Multicystic peritoneal mesothelioma: A short review. ( 28528021 )
2017
45
miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. ( 28716051 )
2017
46
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. ( 28189456 )
2017
47
Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy. ( 29027138 )
2017
48
Benign Multicystic Peritoneal Mesothelioma: A Rare Condition in an Uncommon Gender. ( 28607791 )
2017
49
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. ( 28761723 )
2017
50
Malignant peritoneal mesothelioma, clear cell variant, in a female and its differentiation from clear cell carcinoma. ( 28215643 )
2017

Variations for Peritoneal Mesothelioma

Expression for Peritoneal Mesothelioma

Search GEO for disease gene expression data for Peritoneal Mesothelioma.

Pathways for Peritoneal Mesothelioma

Pathways related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.18 BIRC3 CDKN2A EGFR ESR1
2 11.18 CDKN2A EGFR NF2
3 10.72 LATS2 NF2
4 10.62 EGFR ESR1 WT1

GO Terms for Peritoneal Mesothelioma

Cellular components related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.61 BAP1 BIRC3 CDKN2A EGFR ESR1 LATS2
2 nucleus GO:0005634 9.28 BAP1 BIRC3 CDKN2A EGFR ESR1 LATS2

Biological processes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.67 CDKN2A EGFR ESR1 WT1
2 regulation of apoptotic process GO:0042981 9.63 BIRC3 ESR1 NF2
3 protein deubiquitination GO:0016579 9.61 BAP1 BIRC3 ESR1
4 negative regulation of cell proliferation GO:0008285 9.46 BAP1 CDKN2A NF2 WT1
5 cellular response to estradiol stimulus GO:0071392 9.4 EGFR ESR1
6 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.32 CDKN2A LATS2
7 negative regulation of cell-matrix adhesion GO:0001953 9.26 CDKN2A NF2
8 regulation of inflammatory response GO:0050727 9.13 BAP1 BIRC3 ESR1
9 regulation of toll-like receptor signaling pathway GO:0034121 8.62 BIRC3 ESR1

Molecular functions related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.65 BAP1 BIRC3 CDKN2A EGFR ESR1 LATS2
2 nitric-oxide synthase regulator activity GO:0030235 8.62 EGFR ESR1

Sources for Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....